Robaxin and Xanthelasma - a phase IV clinical study of FDA data
We study 8,758 people who take Robaxin or have Xanthelasma. No report of Xanthelasma is found in people who take Robaxin.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
No report is found.
What is Robaxin?
Robaxin has active ingredients of methocarbamol. It is often used in muscle spasms. eHealthMe is studying from 8,358 Robaxin users for its effectiveness, alternative drugs and more.
What is Xanthelasma?
Xanthelasma (yellow flat plaques over the upper or lower eyelids) is found to be associated with 371 drugs and 275 conditions by eHealthMe.
Do you take Robaxin and have Xanthelasma?Check whether Xanthelasma is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Xanthelasma and when was it recovered:
Expand to all the drugs that have ingredients of methocarbamol:
Alternative drugs to, pros and cons of Robaxin:
- Robaxin (8,358 reports)
Xanthelasma treatments and more:
- Xanthelasma (400 reports)
COVID vaccines that are related to Xanthelasma:
- Xanthelasma in Moderna COVID Vaccine
- Xanthelasma in Pfizer BioNTech Covid Vaccine
- Xanthelasma in Johnson and Johnson Covid Vaccine
All the drugs that are associated with Xanthelasma:
All the conditions that are associated with Xanthelasma:
How the study uses the data?
The study uses data from the FDA. It is based on methocarbamol (the active ingredients of Robaxin) and Robaxin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Daklinza and Gastric Cancer - a second ago
- Herniated Nucleus Pulposus (Slipped Disk) and Psychomotor Hyperactivity - 5 seconds ago
- Repaglinide and Hair Texture Abnormal - 8 seconds ago
- Firmagon and Numbness And Tingling - 8 seconds ago
- Antibiotic Therapy and Biliary Cyst - 18 seconds ago
- Polaramine and Infusion Site Extravasation - 19 seconds ago
- Persantine and Renal Artery Stenosis - 19 seconds ago
- Lipofen and Vytorin drug interaction - 20 seconds ago
- Metoprolol Tartrate and Moviprep drug interaction - 22 seconds ago
- Cinnamon vs. Humulin 70/30 Pen - 24 seconds ago